SOPH (Sophia Genetics) LT-Debt-to-Total-Asset: 0.38 (As of Mar. 2026)

What is Sophia Genetics LT-Debt-to-Total-Asset?

Sophia Genetics SOPH -4.12% 73 LT-Debt-to-Total-Asset is 0.38 as of Mar. 2026. GuruFocus rates SOPH with a GF Score™ of 73/100 and a GF Value™ of $5.04 (Fairly Valued). The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Sophia Genetics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.38.

Sophia Genetics's long-term debt to total assets ratio increased from Mar. 2025 (0.19) to Mar. 2026 (0.38). It may suggest that Sophia Genetics is progressively becoming more dependent on debt to grow their business.

Sophia Genetics (NAS:SOPH) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Sophia Genetics LT-Debt-to-Total-Asset Related Terms

Sophia Genetics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Sophia Genetics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sophia Genetics LT-Debt-to-Total-Asset Chart

Sophia Genetics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.04

0.06

0.08

0.18

0.37

Sophia Genetics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.19	0.35	0.37	0.37	0.38

73GF Score

Sophia Genetics SA SOPH

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Sophia Genetics LT-Debt-to-Total-Asset Calculation

Sophia Genetics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	60.32	/	163.031
	=	0.37

Sophia Genetics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	59.712	/	156.995
	=	0.38

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.38 mean?

Sophia Genetics (SOPH) has a LT-Debt-to-Total-Asset of 0.38 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Sophia Genetics and its competitors.

Is Sophia Genetics' LT-Debt-to-Total-Asset too high?

Sophia Genetics' current LT-Debt-to-Total-Asset is 0.38. Overall, Sophia Genetics has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Sophia Genetics' LT-Debt-to-Total-Asset compare to WEAV and NRC?

Sophia Genetics' LT-Debt-to-Total-Asset of 0.38 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Healthcare Providers & Services company?

A good LT-Debt-to-Total-Asset depends on the Healthcare Providers & Services industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Sophia Genetics and its competitors. Sophia Genetics's current LT-Debt-to-Total-Asset is 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Sophia Genetics stock overvalued right now?

Based on GuruFocus' analysis, Sophia Genetics (SOPH) is currently considered Fairly Valued. The stock's GF Value™ is $5.04, compared to a current price of $5.36 — trading 6.3% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.38. Sophia Genetics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Sophia Genetics (SOPH), the current LT-Debt-to-Total-Asset is 0.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sophia Genetics (SOPH) Overvalued in 2026?

Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued. The current stock price of $5.36 is trading 6.3% above its estimated GF Value™ of $5.04. GuruFocus considers Sophia Genetics to be Fairly Valued.

Key valuation signals for SOPH:

LT-Debt-to-Total-Asset: 0.38
GF Value™: $5.04 vs. price of $5.36 (6.3% above fair value)
GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the SOPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sophia Genetics Business Description

Industry Healthcare Healthcare Providers & Services

Comparable Companies WEAV NRC MDRX CTEV TBRG SLP EVH PHR CARL SPOK VEEV ASX:PME BTSG TEM HQY TSE:2413 HNGE TXG DOCS WAY

Other Exchanges 90B:Germany

Address La Piece 12, Rolle, CHE, CH-1180

Website https://www.sophiagenetics.com

Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.

73GF Score

Get the complete analysis for SOPH

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.36

Price

$5.04

GF Value

View SOPH Analysis

See LT-Debt-to-Total-Asset data for all stocks →